161 related articles for article (PubMed ID: 35197278)
21. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma.
Huang S; Li Y; Hu J; Li L; Liu Z; Guo H; Jiang B; Chen J; Li J; Xiang X; Deng J; Xiong J
J Cell Mol Med; 2021 May; 25(9):4275-4286. PubMed ID: 33834618
[TBL] [Abstract][Full Text] [Related]
22. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
23. N
Tian J; Zhu Y; Rao M; Cai Y; Lu Z; Zou D; Peng X; Ying P; Zhang M; Niu S; Li Y; Zhong R; Chang J; Miao X
Gut; 2020 Dec; 69(12):2180-2192. PubMed ID: 32312789
[TBL] [Abstract][Full Text] [Related]
24. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation, apoptosis, and invasion by sponging miR-625 and miR-892b.
Hao L; Rong W; Bai L; Cui H; Zhang S; Li Y; Chen D; Meng X
J Cell Biochem; 2019 Mar; 120(3):3780-3789. PubMed ID: 30382592
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA‑766 inhibits the malignant biological behaviours of pancreatic ductal adenocarcinoma by directly targeting ETS1.
Li S; Yan G; Yue M; Kang Z; Wang L
Mol Med Rep; 2019 Feb; 19(2):1380-1387. PubMed ID: 30569091
[TBL] [Abstract][Full Text] [Related]
26. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer.
Shimazaki R; Takano S; Satoh M; Takada M; Miyahara Y; Sasaki K; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Sogawa K; Motohashi S; Nomura F; Miyazaki M; Ohtsuka M
Cell Oncol (Dordr); 2021 Aug; 44(4):937-950. PubMed ID: 34075561
[TBL] [Abstract][Full Text] [Related]
27. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Nikiforov MA; Riblett M; Tang WH; Gratchouck V; Zhuang D; Fernandez Y; Verhaegen M; Varambally S; Chinnaiyan AM; Jakubowiak AJ; Soengas MS
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19488-93. PubMed ID: 18042711
[TBL] [Abstract][Full Text] [Related]
28. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
Liu M; Qin Y; Hu Q; Liu W; Ji S; Xu W; Fan G; Ye Z; Zhang Z; Xu X; Yu X; Zhuo Q
Cancer Lett; 2021 Feb; 499():265-278. PubMed ID: 33232789
[TBL] [Abstract][Full Text] [Related]
29. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes K; Hassan Z; Doffo MJ; Schneeweis C; Lier S; Öllinger R; Rad R; Krämer OH; Keller U; Saur D; Reichert M; Schneider G; Wirth M
Mol Oncol; 2020 Dec; 14(12):3048-3064. PubMed ID: 33099868
[TBL] [Abstract][Full Text] [Related]
30. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
Orben F; Lankes K; Schneeweis C; Hassan Z; Jakubowsky H; Krauß L; Boniolo F; Schneider C; Schäfer A; Murr J; Schlag C; Kong B; Öllinger R; Wang C; Beyer G; Mahajan UM; Xue Y; Mayerle J; Schmid RM; Kuster B; Rad R; Braun CJ; Wirth M; Reichert M; Saur D; Schneider G
JCI Insight; 2022 May; 7(10):. PubMed ID: 35439169
[TBL] [Abstract][Full Text] [Related]
32. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic cancer--new aspects of molecular biology research.
Kleeff J; Friess H; Berberat PO; Martignoni ME; Z'graggen K; Büchler MW
Swiss Surg; 2000; 6(5):231-4. PubMed ID: 11077487
[TBL] [Abstract][Full Text] [Related]
34. MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway.
Sun L; Hu L; Cogdell D; Lu L; Gao C; Tian W; Zhang Z; Kang Y; Fleming JB; Zhang W
Autophagy; 2017 Apr; 13(4):703-714. PubMed ID: 28121485
[TBL] [Abstract][Full Text] [Related]
35. Yin Yang-1 suppresses pancreatic ductal adenocarcinoma cell proliferation and tumor growth by regulating SOX2OT-SOX2 axis.
Zhang JJ; Zhu Y; Zhang XF; Liu DF; Wang Y; Yang C; Shi GD; Peng YP; Zhang K; Tian L; Miao Y; Jiang KR
Cancer Lett; 2017 Nov; 408():144-154. PubMed ID: 28867247
[TBL] [Abstract][Full Text] [Related]
36. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
Tzatsos A; Paskaleva P; Ferrari F; Deshpande V; Stoykova S; Contino G; Wong KK; Lan F; Trojer P; Park PJ; Bardeesy N
J Clin Invest; 2013 Feb; 123(2):727-39. PubMed ID: 23321669
[TBL] [Abstract][Full Text] [Related]
37. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
39. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
40. COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.
You N; Li J; Gong Z; Huang X; Wang W; Wang L; Wu K; Zheng L
Mol Carcinog; 2017 Feb; 56(2):607-624. PubMed ID: 27350032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
